Maya Kansara

Head, Translational Oncology Lab

Garvan Institute of Medical Research

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Cancer Biology Cancer Biology professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Maya Kansara is the Head of the Translational Oncology Lab at the Garvan Institute of Medical Research, Australia. Her research focuses on genomic profiling and targeted therapies for various cancers, as evidenced by her recent articles on topics such as NTRK fusions, HER2 amplification, and tumor microenvironments. She is actively involved in studies that explore molecular tumor profiling and treatment matching in rare and advanced cancers.

Articles (14)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (15)

Melissa Green

Professor

University of New South Wales

AUSTRALIA

Maya Kansara

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid Metabolism

Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensing

A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation.

A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling.

Heritable defects in telomere and mitotic function selectively predispose to sarcomas

Ligand-dependent hedgehog signaling maintains an undifferentiated, malignant osteosarcoma phenotype.

A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations

Genomic alterations associated with response to immune checkpoint inhibitors in rare cancers: A biomarker exploration study from the Australian Molecular Screening and Therapeutics (MoST) Program.

Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.

Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.

Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.

Trastuzumab emtansine (T-DM1) in advanced cancers with <i>HER2 </i>mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.

Early circulating tumor DNA dynamics as a pan‐tumor biomarker for long‐term clinical outcome in patients treated with durvalumab and tremelimumab

Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.

Collaborators (15)

Melissa Green

Theresa Corpuz

Swetansu Pattnaik

Paul Timpson

John Grady

Yu Suk Choi

Olga Kondrashova

David Thomas

wei deng

Mandy Ballinger

Luciano Martelotto

Andrew Hoy

Piyushkumar Mundra

Carl Walkley

Andrew Philp

Make your next move.